a review of current treatment options for osteoporosis in bulgaria
Post on 11-Jan-2017
218 Views
Preview:
TRANSCRIPT
www.wjpps.com Vol 4, Issue 05, 2015.
1
Petkova et al. World Journal of Pharmacy and Pharmaceutical Sciences
A REVIEW OF CURRENT TREATMENT OPTIONS FOR
OSTEOPOROSIS IN BULGARIA
Pankova Stefka1, Vasileva Lili
2 and Petkova Valentina
3*
1Department of Pharmacognosy and Pharmaceutical Chemistry, Medical University Plovdiv,
Bulgaria.
2Department of Pharmacology and Clinical Pharmacology, Medical University Plovdiv
Bulgaria.
3Department of Social Pharmacy, Faculty of Pharmacy, Medical University – Sofia,
Bulgaria.
ABSTRACT
Bone undergoes a continuous remodeling process involving resorption
and formation. Any process that disrupts this balance by increasing
resorption relative to formation may results in osteoporosis.
Osteoporosis is defined as abnormal loss of bone predisposing to
fractures. Osteoporosis is characterized by low bone mineral density
(BMD) and loss of the structural and biomechanical properties that are
required to maintain bone homeostasis. This review aims to enlighten
the current trends in prevention and treatment of osteoporosis in
Bulgaria. Recent studies suggest potential role of physical exercises in
prevention and management of osteoporosis. Management of
osteoporosis includes non-pharmacological treatment - diet rich of
calcium and vitamin D, healthy lifestyle, proper exercise plan, and pharmacological therapy.
Combination of non-pharmacological and pharmacological treatment options have to be
considered for prevention of osteoporosis and minimization of the risk of fractures. More
randomized control trial should be done using variable combined methods of treatment.
KEYWORDS: Osteoporosis, treatment, prevention, pharmacology, exercises.
INTRODUCTION
Bone undergoes a continuous remodeling process involving resorption and formation. Any
process that disrupts this balance by increasing resorption relative to formation may results in
WWOORRLLDD JJOOUURRNNAALL OOFF PPHHAARRMMAACCYY AANNDD PPHHAARRMMAACCEEUUTTIICCAALL SSCCIIEENNCCEESS
SSJJIIFF IImmppaacctt FFaaccttoorr 55..221100
VVoolluummee 44,, IIssssuuee 0055,, 0011--1122.. RReevviieeww AArrttiiccllee IISSSSNN 2278 – 4357
Article Received on
11 March 2015,
Revised on 02 April 2015,
Accepted on 23 April 2015
*Correspondence for
Author
Dr. Petkova Valentina
Department of Social
Pharmacy, Faculty of
Pharmacy, Medical
University – Sofia,
Bulgaria.
www.wjpps.com Vol 4, Issue 05, 2015.
2
Petkova et al. World Journal of Pharmacy and Pharmaceutical Sciences
osteoporosis. Osteoporosis is defined as abnormal loss of bone predisposing to fractures.
Osteoporosis is characterized by low bone mineral density (BMD) and loss of the structural
and biomechanical properties that are required to maintain bone homeostasis.[1]
It is most
common in postmenopausal women but also occurs in men. The social burden and annual
direct medical cost of fractures in older people is increasing as our population age
worldwide.[2-5]
It is expected that the number of osteoporotic fractures would double by
2050.[3]
The biggest epidemiological study in Bulgaria was done in 2001 showing the bone
mineral density (BMD) of 8869 women.[3]
Osteoporosis is most commonly associated with
loss of gonadal functions in menopause but may also occur as medication-induced,
idiopathic, or as a consequence of alcohol abuse and smoking. Long-term administration of
glucocorticoids, proton pump inhibitors, selective serotonin receptor inhibitors, androgen
deprivation therapy, thiazolidinediones, heparin, calcineurin inhibitors, and some
chemotherapies such as methotrexate have deleterious effects on bone health.[1]
Management
of osteoporosis includes non-pharmacological treatment - diet rich of calcium and vitamin D,
healthy lifestyle, proper exercise plan, and pharmacological therapy.
RISK FACTORS FOR OSTEOPOROSIS
Age and menopause in women are the two main determinants of osteoporosis and predispose
to low bone mass. In particular, estrogen is a systemic hormone with direct effects on bone
that plays an important role in osteoporosis. In postmenopausal women, the deficiency of
estrogen leads to an upregulation of RANKL on bone marrow cells, resulting in an increase
in bone resorption.[3,5]
The extraskeletal effects of estrogen deficiency are mainly based on
increased renal calcium excretion and decreased intestinal calcium absorption. The risk of
osteoporosis is determined by several independent factors in addition to low bone mass and
decreased estrogen. Family history of fractures, high bone turnover, overweight or too low
body mass index, lack of physical activity, tobacco use, and alcohol abuse, are the most
important factors to be considered.[2,6]
Genetic and nutritional factors (e.g. calcium intake and
vitamin D repletion) play significant roles.[7]
Calcium homeostasis is normally well regulated
such that increased calcium loss via the urine leads to increased calcium absorption from the
gut. However, the duration of this adaptive process may be greater than that of many of the
studies demonstrating that increased salt intake leads to both increased sodium and calcium in
the urine. In any case, higher urinary calcium output appears to be seen only in a minority of
humans in response to increased salt intake. Therefore overuse of salt in the diet is also risk
factor for development of osteoporosis.[6]
www.wjpps.com Vol 4, Issue 05, 2015.
3
Petkova et al. World Journal of Pharmacy and Pharmaceutical Sciences
A quantitative predictor of osteoporotic fractures in postmenopausal women without a
previous fracture is bone mineral density (BMD). The WHO operational definition defines an
osteoporotic woman on the basis of a BMD measurement (spine or hip) showing a T-score
below -2.5. The term “severe or established osteoporosis” habitually denotes a T-score below
-2.5 in the presence of one or more fragility fractures. Osteopenia is defined as a BMD T-
score between -1 and -2.5.[8, 9]
However, BMD alone has a limited value to predict the risk of fractures. The incidence of
osteoporotic fractures increases with age. The predictive value of BMD becomes weaker with
age. It has become evident that fracture risk is also driven by parameters including bone size
and shape, bone turnover, micro-architecture, damage accumulation (micro cracks), and
degree of mineralisation or collagen structure, all playing a role in bone strength, and hence
in the risk of osteoporotic fractures. Several epidemiological studies showed that a large
proportion of incident fragility fractures occur in postmenopausal women who have a BMD
T-score above -2.5. The use of bone-related independent risk factors for fractures combined
with BMD values provides a global assessment of future fracture risk, allowing the
identification of women who should benefit from a treatment to prevent the occurrence of
osteoporotic fractures.[4, 10]
MANAGEMENT AND PREVENTION
Management of osteoporosis includes non-pharmacological treatment - diet rich of calcium
and vitamin D, healthy lifestyle, proper exercise plan, and pharmacological therapy. Both
types of treatment could be implemented for prevention as well as for treatment of
established osteoporosis.
Non-pharmacological treatment
Recent studies suggest potential role of physical exercises in prevention and management of
osteoporosis.[3,5,11-13]
Weight-bearing exercise is associated with increases in bone density.[11]
Krasnova et al report that regular sport activities provided good prophylactic for osteoporosis
within women.[5]
In Bulgaria according to National Guidelines for management of
Osteoporosis 2006-2010 a net of local osteoporosis centers was established.[3]
Prevention
should be initiated early at age by establishing proper sports in schools for children and
adolescents.[13]
The information about risk factors for osteoporosis among young people is
www.wjpps.com Vol 4, Issue 05, 2015.
4
Petkova et al. World Journal of Pharmacy and Pharmaceutical Sciences
important for prevention of letter development of bone problems. Good rehabilitation was
provided with significant decrease in the number of fractures risk patients.[12]
In addition to increase in the physical activity in most elderly patients, alcohol, caffeine and
tobacco use should also be eliminated. These lifestyle modifications can reduce the risk of
fractures. Daily diet should be enriched with calcium and vitamin D.[14]
Numerous studies
have demonstrated the importance of vitamin K in bone health. The results of recent studies
have suggested that concurrent use of menaquinone and vitamin D may substantially reduce
bone loss.[15]
Increased intakes of various nutritional factors (potassium, magnesium, zinc,
vitamin C), fibre and alkaline-producing fruit and vegetables also favour adult bone health.[16]
Pharmacological treatment
Hormone replacement therapy (HRT)
HRT has been shown to reduce the risk of fracture, but increases the risk of breast cancer and
cardiovascular diseases.[4,8,10]
Oestrogens have been used for prevention of bone loss. The
prevailing hypothesis advanced to explain these observations is that estrogens reduce the
bone-resorbing action of PTH. Estrogen receptors have been found in bone, and estrogen has
direct effects on bone remodeling. Case reports of men who lack the estrogen receptor or who
are unable to produce estrogen because of aromatase deficiency noted marked osteopenia and
failure to close epiphyses. This further substantiates the role of estrogen in bone
development, even in men. However, due to recent discussions/developments, there has been
a shift in thinking about the use of medicinal products in osteoporosis. New developments
only for prevention of bone loss after menopause are no longer seen as a goal. The use of
estrogens in this indication is left to local treatment guidelines, which will take into account
both existing data for efficacy and safety.[3]
Selective estrogen receptor modulators (SERMs) have been developed to retain the beneficial
effects on bone while minimizing deleterious effects on breast, uterus, and the cardiovascular
system. Tamoxifen was the first SERM to be widely used in clinical practice, based on its
now well-recognized estrogen antagonist activity in the breast. The prolonged use of
tamoxifen was associated with an increase in uterine cancer, leading to the search for other
SERMs with different pharmacological profiles.[8-10]
Thus, raloxifene, a new SERM, was
developed for the treatment and prevention of postmenopausal osteoporosis, with the goal of
improving the drug safety profile. Raloxifene has a spectrum of tissue-specific agonist-
antagonist effects on estrogen target tissues but acts on bone as an estrogen agonist. This drug
www.wjpps.com Vol 4, Issue 05, 2015.
5
Petkova et al. World Journal of Pharmacy and Pharmaceutical Sciences
has been extensively studied and data support its estrogen agonist profile in the skeletal
system.[10]
The drug specifically acts on estrogenic receptor-a and estrogenic receptor-b,
binding to the receptors in the same ligand-binding pocket as does estradiol, and causes the
C-terminal a-helix of the receptor to change its conformation to block access to the activation
function-2 region of the receptor. This event in turn likely blocks access to the transcriptional
coactivators necessary to facilitate the activation of estrogen-responsive genes. In the
ovariectomized (OVX) rat model, raloxifene acts as an anti-resorptive, with preservation of
both bone mineral density (BMD) and bone strength. It has been demonstrated that raloxifene
modulates the homeostasis of bone cells in vitro by inhibiting osteoclastogenesis and bone
resorption.[17]
Nonhormonal therapy
Nonhormanal forms of therapy for osteoporosis with proven efficacy in reducing fracture risk
include the following pharmacological groups: bisphosphonates, teriparatide, denosumab,
stroncium renalate, calcitonin, calcium and vitamin D.
Biphosphonates
The group of bisphosphonates includes etidronate, pamidronate, alendronate, risedronate,
tiludronate, ibandronate, and zoledronate. Biphosphonates have been conclusively shown to
increase bone density and reduce fractures over at least 5 years when used continuously.[17]
Side-by-side trials between alendronate and calcitonin indicated a grated efficacy of
alendronate. Biphosphonates are poorly absorbed and must be given on an empty stomach or
infused intravenously. At higher oral doses used in the treatment of Paget`s disease,
alendronate causes gastric irritation, but this is not a significant problem at the doses
recommended for osteoporosis. All of these drugs inhibit bone resorption with secondary
effects to inhibit bone formation. They owe at least part of their clinical usefulness and
toxicity to their ability to retard formation and dissolution of hydroxyapatite crystals within
and outside the skeletal system. Some of the newer bisphosphonates appear to increase bone
mineral density well beyond the 2-year period predicted for a drug whose effects are limited
to slowing bone resorption. This may be due to their other cellular effects, which include
inhibition of vitamin D production, inhibition of intestinal calcium transport, metabolic
changes in bone cells such as inhibition of glycolysis, inhibition of cell growth, and changes
in acid and alkaline phosphatase activity. Amino bisphosphonates such as alendronate and
risedronate inhibit farnesyl pyrophosphate synthase, an enzyme in the mevalonate pathway
www.wjpps.com Vol 4, Issue 05, 2015.
6
Petkova et al. World Journal of Pharmacy and Pharmaceutical Sciences
that appears to be critical for osteoclast survival. With the exception of the induction of a
mineralization defect by higher than approved doses of etidronate and gastric and esophageal
irritation by the oral bisphosphonates, these drugs have proved to be remarkably free of
adverse effects when used at the doses recommended for the treatment of osteoporosis.
Esophageal irritation can be minimized by taking the drug with a full glass of water and
remaining upright for 30 minutes or by using the intravenous forms of these compounds.
Biphosphonate-associated maxillary bone osteonecrosis (BPMO) is a complication related to
nitrogen-containing biphosphonate therapy such as zolendronate. This adverse effect
occasionally appears in patients who are administered biphosphonates through intravenous
infusion for the treatment of cancer involving bone metastases. It can also present, in a lesser
degree, in patients who take these drugs orally for the treatment of osteoporosis.[18,19]
More
recently, concern has been raised about over-suppressing bone turnover, and case reports
have appeared describing unusual subtrochanteric (femur) fractures in patients on long-term
bisphosphonate treatment. This complication appears to be rare, comparable to that of
osteonecrosis of the jaw, but has led some authorities to recommend a “drug holiday” after 5
years of treatment if the clinical condition warrants it.[18]
Teriparatide
As osteoporosis is mostly due to bone loss, antiresorptive therapy, mainly bisphosphonates,
are a cornerstone of therapy. However, as a result of their different mode of action, anabolic
drugs have increased the options in the treatment of osteoporosis. Postmenopausal women
and men with severe and progressive osteoporosis despite antiresorptive therapy as well as
patients with glucocorticiod-induced osteoporosis need to be evaluated for a treatment course
with osteoanabolic drugs such as teriparatide. [20]
The recombinant parathormone (PTH) 1-34
teriparatide directly stimulates bone formation. It must be administered daily by subcutaneous
injection. Its efficacy is preventing fractures is at least as great as that of the
bisphosphonates.[17]
Trials examining the sequential use of teriparatide followed by a
bisphosphonate after 1 or 2 years are in progress and look promising. Use of teriparatide with
a bisphosphonate has not shown greater efficacy than the bisphosphonate alone. In all cases,
adequate intake of calcium and vitamin D needs to be maintained.
Calcium
In patients whose dietary intakes do not cover the recommended daily allowances
supplementation with calcium and vitamin D (at daily doses of 1 gr and 800 IU) is needed.[21]
www.wjpps.com Vol 4, Issue 05, 2015.
7
Petkova et al. World Journal of Pharmacy and Pharmaceutical Sciences
Calcium preparations are available for intravenous, intramuscular, and oral administration.
Calcium gluceptate (0.9 mEq calcium/mL), calcium gluconate (0.45 mEq calcium/mL), and
calcium chloride (0.68–1.36 mEq calcium/mL) are available for intravenous therapy.
Calcium gluconate is preferred because it is less irritating to veins.[17]
Oral preparations
include calcium carbonate (40% calcium), calcium lactate (13% calcium), calcium phosphate
(25% calcium), and calcium citrate (21% calcium). Calcium carbonate is often the
preparation of choice because of its high percentage of calcium, ready availability, low cost,
and antacid properties. The association between calcium supplementation and adverse
cardiovascular events has recently become a topic of debate. Several reports indicate that
there is a significant increase in adverse cardiovascular events following supplementation
with calcium; however, a number of experts have raised several issues with these reports such
as inconsistencies in attempts to reproduce the findings in other populations and questions
concerning the validity of the data due to low compliance, biases in case ascertainment,
and/or a lack of adjust- ment. Further studies investigating the risk-benefit profiles of calcium
supplementation in various populations are required to develop population-specific guidelines
for individuals of different genders, ages, ethnicities, and risk profiles around the world.[22]
Vitamin D
Vitamin D alone appears unlikely to be effective in preventing osteoporotic fractures, but in
combination with calcium reduces the risk of new fractures.[3,4,9,14]
When rapidity of action is
required, 1,25(OH) 2 D 3 (calcitriol), 0.25–1 mcg daily, is the vitamin D metabolite of choice
because it is capable of raising serum calcium within 24–48 hours. Calcitriol also raises
serum phosphate, although this action is usually not observed early in treatment. The
combined effects of calcitriol and all other vitamin D metabolites and analogs on both
calcium and phosphate make careful monitoring of these mineral levels especially important
to prevent ectopic calcification secondary to an abnormally high serum calcium × phosphate
product.[17]
Calcitonin
The calcitonin secreted by the parafollicular cells of the mammalian thyroid is a single-chain
peptide hormone with 32 amino acids and a molecular weight of 3600. A disulfide bond
between positions 1 and 7 is essential for biologic activity. The ability of calcitonin to block
bone resorption and lower serum calcium makes it a useful drug for the treatment of Paget’s
disease, hypercalcemia, and osteoporosis. Calcitonin is approved for use in the treatment of
www.wjpps.com Vol 4, Issue 05, 2015.
8
Petkova et al. World Journal of Pharmacy and Pharmaceutical Sciences
postmenopausal osteoporosis.[4,17]
It has been shown to increase bone mass and reduce
fractures, but only in the spine. It does not appear to be as effective as bisphosphonates or
teriparatide.[21]
Denosumab
Denosumab, a human monoclonal antibody, is another antiresorptive agent that has been
approved in Europe and the USA. This agent blocks the RANK/RANKL/OPG system, which
is responsible for osteoclastic activation, thus reducing bone resorption. Naturally RANKL is
molecule produced by osteoblasts. It stimulates osteoclastogenesis via RANK, the receptor
for RANKL that is present on osteoclasts. Denosumab inhibits osteoclast formation and
activity.[23]
It is at least as effective as the potent bisphosphonates in inhibiting bone
resorption and has recently been approved for treatment of postmenopausal osteoporosis and
some cancers (prostate and breast). The latter application is to limit the development of bone
metastases or bone loss resulting from the use of drugs suppressing gonadal function.
Denosumab is administered subcutaneously every 6 months, which avoids gastrointestinal
side effects.[17]
The drug appears to be well tolerated but two concerns remain. First, a
number of cells in the immune system also express RANKL, suggesting that there could be
an increased risk of infection associated with the use of denosumab. Second, because the
suppression of bone turnover with denosumab is similar to that of the potent bisphosphonates,
the risk of osteonecrosis of the jaw and subtrochanteric fractures may be increased, although
this has not been reported in the clinical trials leading to its approval by the FDA.[23]
Stroncium renalate
Furthermore, there are several other forms of therapy in the pipeline. In Europe, strontium
renalate, a drug that appears to stimulate bone formation and inhibit bone resorption, has been
used for several years with favorable results in large clinical trials. However, European
Pharmacovigilance Risk Assessment Committee (PRAC) recommends restriction in the use
of strontium ranelate, based on a routine benefit-risk assessment of the medicine, which
included data showing an increased risk of heart problems, including heart attacks.[4]
On
January 10, 2014 PRAC has recommended that Protelos/Osseor should no longer be used to
treat osteoporosis.[5]
Strontium ranelate is composed of two atoms of strontium bound to an organic ion, ranelic
acid. In Europe, strontium renalate, a drug that appears to stimulate bone formation and
inhibit bone resorption, has been used for several years with favorable results in large clinical
www.wjpps.com Vol 4, Issue 05, 2015.
9
Petkova et al. World Journal of Pharmacy and Pharmaceutical Sciences
trials for the treatment of osteoporosis.[4,24]
Strontium ranelate appears to block differentiation
of osteoclasts while promoting their apoptosis, thus inhibiting bone resorption. At the same
time, strontium ranelate appears to promote bone formation. Unlike bisphosphonates,
denosumab, or teriparatide, this drug increases bone formation markers while inhibiting bone
resorption markers.[17]
Large clinical trials have demonstrated its efficacy in increasing bone
mineral density and decreasing fractures in the spine and hip. However, European
Pharmacovigilance Risk Assessment Committee (PRAC) recommends restriction in the use
of strontium ranelate, based on a routine benefit-risk assessment of the medicine, which
included data showing an increased risk of heart problems, including heart attacks.[24]
On
January 10, 2014 PRAC has recommended that strontium ranelate should no longer be used
to treat osteoporosis.[25-28]
Additional promising new treatments undergoing clinical trials include an antibody against
sclerostin (a protein produced by osteocytes that inhibits bone formation), that has been
shown to stimulate bone formation, and inhibitors of cathepsin K, an enzyme in osteoclasts
that facilitates bone resorption.[17]
DISCUSSION AND CONCLUSION
In conclusion to decrease the risk of osteoporosis the EU guidelines for treatment should be
updated regularly. Patients should be informed in details about the risk factors for fractures.
Establishing a net of local osteoporosis centers in Bulgaria has provided better prophylaxis of
osteoporosis.[3]
Recent Bulgarian studies report that regular sport activities provided good
prophylactic for osteoporosis within women.[5, 12, 13]
Combination of non-pharmacological
and pharmacological treatment options have to be considered for prevention of osteoporosis
and minimization of the risk of fractures.[3, 5, 29-31]
More randomized control trials should be
done using variable combined methods of treatment.
REFERENCES
1. Panday, K., Gona,A ,& Humphrey, M. B. Medication-induced osteoporosis: screening
and treatment strategies. Therapeutic Advances in Musculoskeletal Disease, 2014: 6(5):
185–202.
2. Becker DJ, Kilgore ML, Morrisey MA The societal burden of osteoporosis.Curr
Rheumatol Rep,2010; 12: 186.
3. Национална програма за ограничаване на остеопорозата в България. 2010; 1–18.
www.wjpps.com Vol 4, Issue 05, 2015.
10
Petkova et al. World Journal of Pharmacy and Pharmaceutical Sciences
4. European Medicines Agency. Guideline on the Evaluation of Medicinal Products in the
Treatment of Primary Osteoporosis. Guideline, 2006; 1–10.
5. Dimitrova Dimitrova Z., Vasilev Todorov T, Vasilev Mitov K. Ivanova Petrova G.,
Computerised system for effective stock control management, First congress of pharmacy
of the republic of Macedonia, Skopie, 1995; 41(1-2): 432.
6. Bartlett, J. G., & Thorner, A. R. Risk factors and prevention of, J Musculoskelet Neuronal
Interact.2010; 7: 268–272.
7. Prentice A. Diet, nutrition and the prevention of osteoporosis. Public Health Nutrition,
2004; 7: 227–243.
8. Halldorsson, B. V., Bjornsson, A. H., Gudmundsson, H. T., Birgisson, E. O., Ludviksson,
B. R., & Gudbjornsson, B. A Clinical Decision Support System for the Diagnosis,
Fracture Risks and Treatment of Osteoporosis. Computational and Mathematical
Methods in Medicine, 2015; 1–7.
9. Berry, S. D., Kiel, D. P., Donaldson, M. G., Cummings, S. R., Kanis, J. a., Johansson, H.,
& Samelson, E. J. Application of the national osteoporosis foundation guidelines to
postmenopausal women and men: The Framingham osteoporosis study. Osteoporosis
International, 2010; 2(1): 53–60.
10. Sale, J. E. M., Gignac, M. a, Hawker, G., Frankel, L., Beaton, D., Bogoch, E., & Elliot-
Gibson, V. Decision to take osteoporosis medication in patients who have had a fracture
and are “high” risk for future fracture: a qualitative study. BMC Musculoskeletal
Disorders, 2011; 12(1): 92.
11. Te, H., Shea, B., Lj, D., Downie, F., Murray, a, Ross, C. Exercise for preventing and
treating osteoporosis in postmenopausal women (Review). Cochrane Database Syst Rev.
2011; 6(7): CD000333.
12. Kasnakova P., Velikov Y. Methodology of complex rehabilitation in cases of disk
nemiation. Trakia Journal of Sciences, 2012; 10(3): 185-187.
13. Kasnakova P., Krushkova P., Kostov S., Slavcheva N. Importance of sports and aerobic
exercise for prevention of obesity among children and adolescents. Proceeding book XVI
International Scientific Congress “Olympic Sport and Sport for All” & VI International
Scientific Congress “Sport, Stress, Adaptation”, Sofia May, 2012; 17-19, 479-481.
14. Avenell, a, Wj, G., Ld, G., Connell, O. D., Avenell, A., Gillespie, W. J, Connell, D. O.
Vitamin D and vitamin D analogues for preventing fractures associated with involutional
and post-menopausal osteoporosis ( Review ) Cochrane Database Syst Rev. 2009; (3): 2–
4.
www.wjpps.com Vol 4, Issue 05, 2015.
11
Petkova et al. World Journal of Pharmacy and Pharmaceutical Sciences
15. Adams, J., & Pepping, J. Vitamin K in the treatment and prevention of osteoporosis and
arterial calcification. American Journal of Health-System Pharmacy : AJHP : Official
Journal of the American Society of Health-System Pharmacists, 2005; 62(15): 1574–81.
16. Cohen, A., Roe, F. J. Review of risk factors for osteoporosis with particular reference to a
possible aetiological role of dietary salt. Food and Chemical Toxicology, 2000; 38(2-3):
237–253.
17. Katzung, B. G., Masters, S. B., & Trevor, A. J. Basic and clinical Pharmacology.
18. López-D’alessandro, E., Mardenlli, F., & Paz, M. Oral bisphosphonate-associated
osteonecrosis of maxillary bone: A review of 18 cases. Journal of Clinical and
Experimental Dentistry, 2014; 6(5): e530–4.
19. Polymenidi, I., Trombetti, A., & Carballo, S. The risk of bisphosphonate-related
osteonecrosis of the jaw]. Revue Médicale Suisse, 2014; 10(446): 1930–4.
20. Meier, C., Lamy, O., Krieg, M., Mellinghoff, H., Felder, M., Ferrari, S., & Rizzoli, R.
The role of teriparatide in sequential and combination therapy of osteoporosis, 2014; 1–6.
21. Reginster, J.-Y., Neuprez, A., Lecart, M. P., Sarlet, N., Distèche, S., & Bruyère, O.
[Treatment of post-menopausic osteoporosis: what’s new in 2014?]. Revue Médicale de
Liège, 2014; 69(7-8): 441–53.
22. Shin, C. S., & Kim, K. M. Review Article The Risks and Benefits of Calcium
Supplementation, Endocrinology and Metabolism,2015; 30: 27–34.
23. Nardone, V., D’Asta, F., Brandi, M. L. Pharmacological management of osteogenesis.
Clinics (São Paulo, Brazil), 2014; 69(6): 438–46.
24. European Medicines Agency PRAC recommends suspending use of Protelos / Osseor
( strontium ranelate ) Recommendation by PRAC to be considered by CHMP for final
opinion, 2014; 44: 1–2.
25. European Medicines Agency PRAC recommends suspending use of Protelos / Osseor (
strontium ranelate ) Recommendation by PRAC to be considered by CHMP for final
opinion, 2014; 44: 1–2.
26. Dimitrova Dimitrova Z., Vasilev Todorov T, Vasilev Mitov K. Ivanova Petrova G.,
Computerised system for effective stock control management, First congress of pharmacy
of the republic of Macedonia, Skopie, 1995; 41(1-2): 432.
27. Kamusheva M., Mitov K., G. Petrova. Еconomic impact of the influenza prophylaxis with
influenza vaccine (split virion, inactivated) among elderly patients >65 years old in
Bulgaria. World journal; of pharmacy and pharmaceutical sciences, 2015; 4 (3): 24-36.
www.wjpps.com Vol 4, Issue 05, 2015.
12
Petkova et al. World Journal of Pharmacy and Pharmaceutical Sciences
28. Georgieva Svetla, Maria Kamusheva, Dragana Lakic, Konstantin Mitov, Alexandra
Savova, Guenka Petrova, The health related quality of life for kidney transplant patients
in bulgaria – a pilot study, Biotechnology & Biotechnol. Eq, 2012, 26(3): 3062-3065.
29. Naseva E., T. Kundurzhiev. Tabular and graphical presentation of data. In: Occupational
Medicine and Public Health, Part Three Statistics in occupational medicine, Edited by
prof. N. Tsacheva, MU-Sofia, 2015; 21-32. ISBN 978-954-9493-92-4.
30. Kundurzhiev T., F. Naseva. Parametric methods for hypotheses testing. In: Occupational
Medicine and Public Health, Part Three Statistics in occupational medicine, Edited by
prof. N. Tsacheva, MU-Sofia, 2015; 60-66. ISBN 978-954-9493-92-4.
31. Gardeva M., E. Naseva. Needs assessment of health services in practice for immediate
assistance and distribution of regulatory standards. Medical meridians, 2013; 2: 24-31.
top related